The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China

被引:9
|
作者
Zheng, Huan Jie [1 ]
Ouyang, Shu Kun [1 ]
Zhao, Yue [1 ]
Lu, Kai [1 ]
Luo, Su Xin [1 ]
Xiao, Hua [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, 1 Youyi Rd, Chongqing 400016, Peoples R China
关键词
atrial fibrillation; anticoagulation therapy; oral anticoagulant; antiplatelet therapy; international normalized ratio; STROKE PREVENTION; HOSPITALIZED-PATIENTS; ORAL ANTICOAGULANTS; WARFARIN; ASPIRIN; THERAPY; RISK; METAANALYSIS; CLOPIDOGREL; EVENTS;
D O I
10.2147/IJGM.S128047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Oral anticoagulants (OACs) are effective for the prophylaxis of stroke in patients with atrial fibrillation (AF). This cross-sectional study aimed to investigate the status of anticoagulation treatment for hospitalized AF patients in Southwest China. Methods: A total of 4760 hospitalized patients with AF were enrolled from 21 hospitals in Chongqing city from January 1 to December 31, 2013. Results: Among the enrolled patients, 3785 were diagnosed with nonvalvular AF. These patients had a mean age of 74.4 +/- 10.1 years. The mean CHADS(2) score of all subjects was 2.60 +/- 1.34, and 80.7% of the patients had CHADS(2) >= 2. The use rate of OACs was only 11.5% for patients with a high risk for stroke (CHADS(2) >= 2) and was much lower in patients from the second-level hospitals than in patients from the third-level hospitals (5.8% vs. 16.9%, P<0.001). The leading reason for the underuse of OACs in high-risk patients was physician's nonfeasance. Conclusion: This study demonstrated that the underuse of anticoagulation therapy in hospitalized patients with nonvalvular AF was particularly serious in Southwest China, especially in the second-level hospitals. Urgent and effective measures are desperately needed to improve this alarming situation in China.
引用
收藏
页码:69 / 77
页数:9
相关论文
共 50 条
  • [21] Utilization of Anticoagulation Therapy in Medicare Patients with Nonvalvular Atrial Fibrillation
    Broulette, Jonah
    Pyenson, Bruce
    Iwasaki, Kosuke
    Kwong, Winghan Jacqueline
    Murphy, Michael F.
    AMERICAN HEALTH AND DRUG BENEFITS, 2012, 5 (03):
  • [22] New Anticoagulation Drugs for Atrial Fibrillation
    Potpara, T. S.
    Lip, G. Y. H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (04) : 502 - 506
  • [23] Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation - The anticoagulation and risk factors in atrial fibrillation (ATRIA) study
    Go, AS
    Hylek, EM
    Phillips, KA
    Borowsky, LH
    Henault, LE
    Chang, YC
    Selby, JV
    Singer, DE
    CIRCULATION, 2000, 102 (01) : 11 - 13
  • [24] Current use of oral anticoagulation therapy and influencing factors among coronary artery disease patients with nonvalvular atrial fibrillation in China
    乔岩
    ChinaMedicalAbstracts(InternalMedicine), 2023, 40 (03) : 163 - 163
  • [25] Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status
    José Felipe Varona
    José Miguel Seguí-Ripoll
    Cristina Lozano-Duran
    Luis Miguel Cuadrado-Gómez
    Juan Bautista Montagud-Moncho
    Antonio Ramos-Guerrero
    José Carlos Mirete-Ferrer
    Esther Donado
    Javier García-Alegría
    Health and Quality of Life Outcomes, 18
  • [26] Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status
    Varona, Jose Felipe
    Segui-Ripoll, Jose Miguel
    Lozano-Duran, Cristina
    Cuadrado-Gomez, Luis Miguel
    Montagud-Moncho, Juan Bautista
    Ramos-Guerrero, Antonio
    Mirete-Ferrer, Jose Carlos
    Donado, Esther
    Garcia-Alegria, Javier
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2020, 18 (01)
  • [27] Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting
    Han, Seol Young
    Palmeri, Sebastian T.
    Broderick, Samuel H.
    Hasselblad, Vic
    Rendall, Dave
    Stevens, Scott
    Tenaglia, Alan
    Velazquez, Eric
    Whellan, David
    Wagner, Galen
    Heitner, John F.
    JOURNAL OF ELECTROCARDIOLOGY, 2013, 46 (01) : 45 - 50
  • [28] Anticoagulation in women with nonvalvular atrial fibrillation: insights from clinical trials
    Reynolds, Deborah A.
    Halperin, Jonathan L.
    WOMENS HEALTH, 2007, 3 (06) : 673 - 678
  • [29] Personalizing Bridging Anticoagulation in Patients with Nonvalvular Atrial Fibrillation—a Microsimulation Analysis
    Matthew A. Pappas
    Geoffrey D. Barnes
    Sandeep Vijan
    Journal of General Internal Medicine, 2017, 32 : 464 - 470
  • [30] Anticoagulation control for nonvalvular atrial fibrillation in a tertiary academic centre in Johannesburg
    Mogashoa, Vanessa
    Mpanya, Dineo
    Tsabedze, Nqoba
    THROMBOSIS JOURNAL, 2024, 22 (01):